This antibiotic may work today……
……but what about tomorrow
The world is already facing a ‘Discovery Void’ in novel antibiotics:
While many antibiotics have long timelines before they succumbed to AMR, the last four antibotics developed over the last 30 years failed within twelve months of product launch……….
While some classes of antibiotics fare better than others, there is now a critical need for developing new classes of antibiotics…….
Currently, AMR is responsible for approximately 1 million deaths annually
It is estimated that over 10 million people will die annually from AMR by 2050….
The problem is that current conventional drug discovery assays and screens based on the strength or affinity of binding are considered incapable of being used to mine the next generation of biocides and antimicrobials, particularly ones that are either resistant to the AMR mechanism itself or are directed towards new targets within the microbiome
New approaches in drug discovery are urgently needed
The need for disruptive platforms for delivering next-generation antibiotics is summarised below:
[Modified from: https://www.nature.com/articles/nrd3975]
BioPharm Enterprises is focusing its resources to introduce biophysical screening as an alternative approach for fast-track development of next-generation antimicrobial therapeutics